Executive Vice President and Chief Medical Officer at Ayala Pharmaceuticals
RINGSIDE phase 2 data in desmoid tumors show that AL102 1.2 mg once daily achieved ORR of 83% and reduction in tumor volume and in T2W signal intensity in 88% and 85% of the evaluable population, respectively. The Ayala team is very grateful to the patients, their families and the investigators participating in the study. #desmoid #GSI #AL102 #RINGSIDE
A new breakthrough platform will enable non-invasive clinical assays in time for clinical decision. The “Rapid, Reproducible, Rare Cell 3D Expansion” (R3CE) is able to generate solid tumors, rare cells, Circulating-Tumor-Cells (CTCs) and more. This opportunity will allow physicians to accurately predict drug resistance acquired over treatment cycles. It was developed by Dr. Mark D Pegram, Dr. Ying C Chang, Dr. Wen-Hung Kuo, Dr. Yu Zong, Dr. Yen-Jang Huang, and Dr. Jia-Yang Chen. Read more about the R3CE’s capabilities here ⬇️ https://lnkd.in/gsyY4YMY
Chief Medical Officer at Nexus Alliance Biopharmaceuticals, a currently practicing MD.
“Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” There are more than 150 active INDs associated with BRAF targeted and combination therapy across all indications. This is the second largest sub population solid tumor active efforts in precision medicine in R/R groups. Combinations are increasing along T & B cell combination targets.
I am happy to share our research publication, " Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy." This article has been published in #BiomaterialsAdvances (Impact Factor 7.9; Scopus Q1). Article link: https://lnkd.in/gdkHHyVk #PublicationAlert #PharmaceuticalSciences #PharmaceuticalResearch #BiomaterialsAdvances #Elsevier
Business Development Manager | Agricultural Adjuvants and Agrochemical Performance Specialist | MSc Organic Chemistry (UCT)
Proud to have been able to contribute to this research. Another great article, assessing ADC and recombinant photo-activated therapeutic efficacy for light-accessible and light-inaccessible tumors. https://lnkd.in/dFwTibUM
Tumor infiltrating lymphocytes: complex science, but maybe even more complex launch. At 515K$ per treatment, Iovance will face challenges. TIL therapy originated from research at the National Institutes of Health in the 1980s. It took decades to fine-tune, and Iovance had to overcome multiple regulatory delays bringing the therapy, formerly known as lifileucel, to market. Its clearance is the “culmination of scientific and clinical research efforts,” https://lnkd.in/ebbBwVr3
Pan-cancer biomarkers and therapies are an exciting development in the field of cancer treatment, as they offer new hope for patients who may not have precision therapies developed for their specific disease. The growth of our INFORM clinical-genomics database is also exciting, as it provides the evidence to refine ever more targeted therapies. Let's continue to push the boundaries of cancer research and treatment! #cancerresearch #precisionmedicine #clinicalgenomics
Proud of this one! 🚀 "These data support use of a well-validated ctDNA assay to detect MSI-H across solid tumors and suggest prolonged PFS in patients treated with IO-containing regimens after detection. Tumor-agnostic, ctDNA-based MSI testing may be reliable for rapid decision making." https://lnkd.in/gSQ3YkAu
Altamira Therapeutics is breaking barriers in #RNATherapeutics with our OligoPhore™ / SemaPhore™ technology. Our versatile system complexes therapeutic RNAs with a proprietary peptide to create nanoparticle formulations. These formulations enable systemic delivery of therapeutic RNA to tissues affected by leaky vasculature, a common feature in solid tumors and specific inflammatory conditions. Our mission extends beyond innovation; it's about creating real-world impact. We plan to advance our flagship programs to IND/Phase I and leverage the OligoPhore™ / SemaPhore™ platforms through collaboration with partners in well-defined additional therapeutic areas. Learn more here: https://bit.ly/3JjIBix #Science #mRNA #siRNA
Genetic Counselor, Genomic Policy and Value Researcher, Utilization Management, Medical Affairs, Managed Care and Market Access for Genetic Testing
Guardant360 #liquidbiopsy is well-validated to detect microsatellite instability high tumors and those same patients treated with FDA approved immunotherapy have better outcomes. This is a great set of #pancancer #multicancer cohort data and goes far in showing that guidelines and coverage policies can include #comprehensivegenomicprofiling in a specimen and tumor agnostic manner. Great work on this paper!!!
Proud of this one! 🚀 "These data support use of a well-validated ctDNA assay to detect MSI-H across solid tumors and suggest prolonged PFS in patients treated with IO-containing regimens after detection. Tumor-agnostic, ctDNA-based MSI testing may be reliable for rapid decision making." https://lnkd.in/gSQ3YkAu
Zotiraciclib is a kind of precision medicine for IDH-mutant gliomas. - Jing Wu, M.D., Ph.D. After Pacritinib (approved by FDA in 2022), another asset discovered by Singapore biotech S*BIO; (2000-2011) CDK inhibitor, Zotiraciclib is showing promising activity in glioblastoma. Clinical trials in progress to assess Zotiraciclib as a treatment for people with recurrent gliomas containing an IDH1 or IDH2 mutation to control tumor growth and improve quality of life. https://lnkd.in/gaJ2RTn3
Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch
Business Development (CDMO) | North America | Small molecules | Peptides | API | Intermediates | RSM | KSM | Deuterated Molecules | Carbohydrates | Chiral Compounds | IND and NDA Filing
10moGood luck with AL102 David Caron Ronen Ben-David